A Phase I Study to Determine the Maximum Tolerated Dose and Safety of Oral LR-103 (1α,24(S)Dihydroxyvitamin D(2)) in Patients with Advanced Cancer

BACKGROUND: The objective of this study was to determine the maximum tolerated dose (MTD) and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer. METHODS: In Step A, patients received once daily oral LR-103 in 14-day cycles with intra-patient dose escalation per accelerated dos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Oncol Pharm Pract
Hauptverfasser: Wisinski, Kari B, Ledesma, Wendy M, Kolesar, Jill, Wilding, George, Liu, Glenn, Douglas, Jeffrey, Traynor, Anne M, Albertini, Mark, Mulkerin, Daniel, Bailey, Howard H
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281509/
https://ncbi.nlm.nih.gov/pubmed/24986793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1078155214541572
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge